TY - JOUR
T1 - Salsalate kinetics in patients with chronic renal failure undergoing hemodialysis
AU - Williams, Mark E.
AU - Weinblatt, Michael
AU - Rosa, Robert M.
AU - Griffin, Victoria L.
AU - Goldlust, M. Barry
AU - Shang, Shaw F.
AU - Harrison, Lester I.
AU - Brown, Robert S.
PY - 1986/4
Y1 - 1986/4
N2 - A 1500 mg dose of salsalate (SSA) was given to five patients undergoing chronic hemodialysis on an interdialytic day and again before dialysis. Compared with control subjects, patients undergoing dialysis had a lower peak plasma SSA level (17 ± 3 vs. 45 ± 2 μg/ml; P < 0.01) that occurred slightly later. In contrast, plasma salicylic acid (SA), the active SSA metabolite, had a similar but later peak level that remained substantially higher. Therefore, the AUC for SA was increased by 50% and the SA t½was prolonged in the patients receiving dialysis (8.1 ± 0.7 vs. 3.8 ± 0.2 hours; P < 0.01). During a single treatment, dialysis clearance reduced plasma SA levels, removed 18% of total body SA, and returned the SA t½to nearly normal. Because the elimination of SA is impaired in patients undergoing dialysis, the interdialytic SSA dosage should be reduced. Hemodialysis improves SA kinetics and may be followed by a normal SSA replacement dose. However, periodic monitoring of plasma SA levels is recommended when SSA dosing is begun in patients receiving dialysis. Clinical Pharmacology and Therapeutics (1986) 39, 420–424; doi:
AB - A 1500 mg dose of salsalate (SSA) was given to five patients undergoing chronic hemodialysis on an interdialytic day and again before dialysis. Compared with control subjects, patients undergoing dialysis had a lower peak plasma SSA level (17 ± 3 vs. 45 ± 2 μg/ml; P < 0.01) that occurred slightly later. In contrast, plasma salicylic acid (SA), the active SSA metabolite, had a similar but later peak level that remained substantially higher. Therefore, the AUC for SA was increased by 50% and the SA t½was prolonged in the patients receiving dialysis (8.1 ± 0.7 vs. 3.8 ± 0.2 hours; P < 0.01). During a single treatment, dialysis clearance reduced plasma SA levels, removed 18% of total body SA, and returned the SA t½to nearly normal. Because the elimination of SA is impaired in patients undergoing dialysis, the interdialytic SSA dosage should be reduced. Hemodialysis improves SA kinetics and may be followed by a normal SSA replacement dose. However, periodic monitoring of plasma SA levels is recommended when SSA dosing is begun in patients receiving dialysis. Clinical Pharmacology and Therapeutics (1986) 39, 420–424; doi:
UR - http://www.scopus.com/inward/record.url?scp=0022457581&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022457581&partnerID=8YFLogxK
U2 - 10.1038/clpt.1986.65
DO - 10.1038/clpt.1986.65
M3 - Article
C2 - 3956057
AN - SCOPUS:0022457581
SN - 0009-9236
VL - 39
SP - 420
EP - 424
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 4
ER -